FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why

Rahul Rao, the deputy director of the FTC Bureau of Competition, discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.

• Source: Shutterstock

Rahul Rao, deputy director of Federal Trade Commission's Bureau of Competition, said the regulatory group’s tougher stance on pharmaceutical deals stems from a general view that market incentives in the sector had grown misaligned with competitive practices.

Key Takeaways

  • FTC Bureau of Competition Deputy Director Rahul Rao no seismic event lead to the agency’s recent actions on pharma deals.

“There wasn’t a seismic event that happened,” he said. “What we are seeing is greater consolidation. We’re seeing the effects...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet